scholarly journals Managing two decades of visceral leishmaniasis and HIV co-infection: a case report that illustrates the urgent research needs in the field

Sexual Health ◽  
2017 ◽  
Vol 14 (3) ◽  
pp. 286 ◽  
Author(s):  
Melissa L. Kelly ◽  
Angie N. Pinto ◽  
Dan Suan ◽  
Debbie Marriott ◽  
David A. Cooper ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Case Report ◽  
Side Effects ◽  
Visceral Leishmaniasis ◽  
Liver Failure ◽  
Infected Patient ◽  
Poor Quality ◽  
Research Needs ◽  
Treatment Side Effects

Visceral leishmaniasis and HIV co-infection presents diagnostic, monitoring and treatment challenges. This is a report of a co-infected patient who developed multiple complications and treatment side-effects, including renal and liver failure, pancytopenia with recurrent sepsis, along with anal cancer, depression and poor quality-of-life spanning over two decades. Urgent research specific to this cohort is needed.

scholarly journals BIOBRAN MGN-3

2012 ◽  
Vol 20 (01) ◽  
pp. 13-16
Author(s):  
Ahmad Ijaz Masood ◽  
RABEETA SHEIKH ◽  
RANA ATIQUE ANWER
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Hair Loss ◽  
White Blood Cells ◽  
Food Supplement ◽  
Severe Nausea ◽  
Treatment Side Effects ◽  
Group A ◽  
Group B

Objective: The aim of study was to assess the effect of Biobran in reducing of chemotherapy induced side effects in termsof tiredness, anorexia, vomiting and hair loss and quality of life in terms of weight loss. Setting: Radiotherapy Department, NishtarHospital Multan. Material and Methods: Fifty patients of breast cancer were enrolled randomly in two groups. Group-A patients weregiven 3 gram dose of Biobran MGN-3 per day one week before and one week after chemotherapy. Group-B patient were givenchemotherapy alone. Total six cycles of chemotherapy were given. No multivitamin or food supplements were given during this study.Chemotherapy induced side effects (tiredness, anorexia, and vomiting, hair loss) were assessed by questionnaire to the patients beforestart of each cycle. Weight was checked before each cycle to assess weight gain or loss. White blood cells were checked by completeblood count just before and one week after chemotherapy. Results: Between six months, 50 patients were enrolled in RadiotherapyDepartment, Nishtar Hospital Multan. There was a significant reduction in tiredness and anorexia in group-A patients. 20 (80%) patients ofgroup-A felt increase in their diet and no tiredness without any appetizer or multivitamin. But group-B patients demanded for appetizer dueto severe anorexia after chemotherapy except 3 (12%) patients who didn’t use any appetizer or food supplement. In group-A, 15 (60%)patients didn’t need any anti-emetic as compared to group-B all patient (100%) experienced severe nausea during and afterchemotherapy. Group-A patients experienced less hair fall 7 (28%) patients as compared to other group which is 25 (100%) patients.Conclusions: The study showed that, by helping to optimize the immune system, Biobran MGN-3 can not only help maximize treatmentsuccess, but also minimize treatment side effects and improve quality of life during treatment and in recovery.

scholarly journals When Eating Becomes Torturous: Understanding Nutrition-Related Cancer Treatment Side Effects among Individuals with Cancer and Their Caregivers

Nutrients ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 356
Author(s):  
Brandy-Joe Milliron ◽  
Lora Packel ◽  
Dan Dychtwald ◽  
Cynthia Klobodu ◽  
Laura Pontiggia ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Cancer Treatment ◽  
Food Preferences ◽  
Treatment Side Effects ◽  
Food And Nutrition ◽  
Loss Of Appetite ◽  
Living With Cancer ◽  
Depth Interviews

Individuals living with cancer often experience multiple nutrition-related side effects from cancer treatment, including changes in taste and smell, nausea, diarrhea, loss of appetite, and pain during eating. These side effects can profoundly impact nutritional status and quality of life. The purpose of this study was to explore experiences with nutrition-related cancer treatment side effects among cancer patients and their family caregivers, the way they manage such side effects, and the resulting changes in food preferences and behaviors. Structured surveys and in-depth interviews were conducted. Interviews focused on the presence and management of treatment side effects, how those changes influenced food preferences, and the extent to which they interfered with quality of life. Most patients (72%) reported treatment side effects; 61% reported that these side effects impacted their eating and drinking. Common side effects included fatigue (58%), dry mouth (30%), nausea (24%), constipation (20%) and diarrhea (20%). Six overarching qualitative themes were identified: Spiral of side effects; Pain of eating; Burden of eating; Loss of taste/change in taste; Symptom management; and Solutions. The authors conclude with implications for food and nutrition practice—moving beyond traditional recommendations of what to eat or avoid—to consider the overall patient and caregiver experience.

On Cancer Nanotechnology

2010 ◽  
Vol 441 ◽  
pp. 307-332
Author(s):  
Rita Bosetti ◽  
Lode Vereeck
Keyword(s):  
Quality Of Life ◽  
Cancer Research ◽  
Side Effects ◽  
Cancer Biology ◽  
Causes Of Death ◽  
Poor Quality ◽  
Therapeutic Agents ◽  
Target Cells ◽  
Patients Experience

Although governments invest billions of dollars in cancer research, cancer remains one of the major causes of death worldwide (Liu et al., 2007). During the last decades, outstanding results have been attained in fundamental cancer biology but, unfortunately, they have not been translated in even distantly comparable progressions in the clinic. The main reason for this gap being the inability to administer therapeutic agents so that they can reach target cells without or with minimal side-effects (Ferrari, 2005). Today, scientists are faced with the recognition that very few molecules reach the desired locations and thus fail to selectively reach the target cells. Consequently, patients experience a very poor quality of life (Ferrari, 2004; Ferrari, 2005; Chan, 2006).

Worry about quality of life for younger versus older adult thyroid cancer survivors.

2019 ◽  
Vol 37 (27_suppl) ◽  
pp. 157-157
Author(s):  
Stefanie Marie Thomas ◽  
David Reyes-Gastelum ◽  
Joel Milam ◽  
Kimberly Ann Miller ◽  
Anamara Ritt-Olson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Decision Making ◽  
Thyroid Cancer ◽  
Side Effects ◽  
Age Differences ◽  
Amount Of Information ◽  
Treatment Side Effects ◽  
Younger Age ◽  
Multivariable Analyses

157 Background: Thyroid cancer is one of the most common cancers in young adults, age 18-39 years. Since this population has distinct medical and developmental needs, it is important to understand age differences in worry about quality of life. Methods: Thyroid cancer patients diagnosed between 2014-15 were accrued from the Surveillance, Epidemiology and End Results Program (SEER) registries of Georgia and Los Angeles County and surveyed between 2017-18. The primary outcome was patient reported worry about quality of life. Covariates for this analysis included age (categorized 18-25, 26-39, 40-64, and 65-79), involvement in surgical decision making (low, just right, high) and amount of information received on treatment side effects (low, just right, high). Race/ethnicity, sex, and tumor characteristics were also evaluated. Multivariable analyses were used to assess associations between worry about quality of life and independent variables. Results: In the cohort of 2,632 patients, 39.8% were somewhat to very much worried about quality of life not being the same as before thyroid cancer diagnosis, 15.1% reported low involvement in surgical decision making, and 32.6% reported low amount of information regarding side effects. Younger age was associated with high worry about quality of life (p < 0.001), low involvement in decision making (p < 0.001) and low amount of information on treatment side effects (p < 0.001). In multivariable analyses, high worry was significantly associated with female sex (Odds ratio [OR]: 1.29 95% confidence Interval [CI]:1.04-1.59), non-white, non-Hispanic race/ethnicity (OR: 1.64 CI: 1.38-1.95), positive lymph nodes (OR: 1.41 CI: 1.14-1.75) and younger age (ages 18-25 years OR: 2.34 CI: 1.45-3.76; ages 26-39 years OR: 2.26 CI: 1.68-3.05; and ages 40-64 years OR:1.94 CI 1.50-2.51). Age differences remained significant after adding either involvement in decision-making or information received. Conclusions: Young adults report higher worry about quality of life. Controlling for decision-making involvement or information received about side effects did not eliminate age differences in worry. Ongoing psychosocial support addressing quality of life worries among younger survivors is needed.

Quality of life intervention for men with biochemical recurrence of prostate cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 18585-18585
Author(s):  
W. Tan ◽  
S. Ames ◽  
A. Gretchen ◽  
R. Stone ◽  
T. Rizzo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Side Effects ◽  
Biochemical Recurrence ◽  
Research Approach ◽  
Treatment Needs ◽  
Treatment Side Effects ◽  
Psa Testing ◽  
The Impact

18585 Background: The Quality of life (QOL) and psychosocial needs of the 30–40% of prostate cancer patients who experience biochemical recurrence are not known. The impact of having a rising PSA, anticipation of undergoing PSA testing, and living with prostate cancer may increase psychological distress and decrease QOL. Aim: to evaluate the psychosocial treatment needs of men with biochemical recurrence of prostate cancer (br-PCa) and to develop a treatment to address these needs. Methods: 28 men with br-PCa, 58–87 years, were enrolled. A qualitative research approach was used, consisting of six, 2 hour, semi-structured, focus groups containing 4–6 men per group. Data were content coded and grouped into categories following the structure of the focus group guide. The major conceptual themes were then summarized by 2 independent reviewers. Discrepancies were discussed with a third researcher until a consensus was reached. These results were used to guide development of a multi-disciplinary quality of life intervention. Results: Participants defined QOL as the ability to stay active both physically and mentally without limitation in the performance of usual activities. There was a consensus that prostate cancer led to substantial anxiety related to PSA testing, treatment side effects, and fear of recurrence. Participants were enthusiastic about receiving adjuvant multidisciplinary treatment for prostate cancer focusing on anxiety management, nutrition, exercise, management of treatment side effects, and medical education. Participants desired a male group leader and feedback was mixed regarding whether spouses should be involved. Conclusions: Men with br-PCa report experiencing substantial anxiety and were enthusiastic about receiving a structured intervention to these needs. Based on our findings an intervention has been developed and is currently being compared to usual care. No significant financial relationships to disclose.

Do drugs that offer PFS or modest OS benefits improve quality of life in patients with advanced cancer?

2017 ◽  
Vol 35 (5_suppl) ◽  
pp. 223-223
Author(s):  
Lesley Fallowfield ◽  
Susan L. Catt ◽  
Shirley F May ◽  
Valerie M Shilling ◽  
Lucy A Matthews ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Symptom Burden ◽  
Cancer Control ◽  
Progression Free Survival ◽  
Well Being ◽  
Treatment Side Effects ◽  
Time Interaction ◽  
Group B

223 Background: Patients value quality of life (QoL) not just quantity of life but QoL data from measures in advanced disease are sparse for drugs with only progression-free survival (PFS) or modest overall survival (OS) benefits. We examined if stabilisation of metastatic disease and/or disease symptom burden were worth treatment side effects in the AVALPROFS study. Methods: Patients with metastatic cancers starting drugs with PFS or modest OS benefits were interviewed at baseline and following 6 weeks of treatment. Further interviews were conducted at progression or if treatment was stopped for toxicity. Interviews comprised trade-off type assessments exploring worthwhileness of treatment compared with side effects.Patients completed FACT tumor and treatment specific questionnaires monthly for 6 months. Global QoL was measured across time and between patients who died or progressed on study (A), remained on study (B) or withdrew from study due to toxicity (C). Results: 90/120 (75%) eligible patients participated. 31/90 (21%) patients died or progressed within 6 months of study entry (Group A). 12 patients withdrew due to toxicity (Group B) and 47 patients stayed on treatment for 6 months (Group C). At first interview 43/90 (48%) patients had started treatment and by 6 weeks (66/69, 96%) were experiencing side effects. At both interviews patients were significantly less inclined to feel that benefits of cancer control were worthwhile as the possible side effect severity increased (X2=75.6004. p< 0.00001; 50.6896 p< 0.00001 respectively). There was an effect of patient group on general QoL (F=4.978; p = 0.007) but no group by time interaction (F=0.419; p = 0.888). Also, a significant overall group effect (A vs. C) for emotional (F=6.583, p = 0.011) and functional well-being (F=5.138, p = 0.024). More patients in Group C had stable/improved QoL over time. Conclusions: Over 6 months, QoL was stable in those patients receiving drugs with PFS only or minimal OS who could tolerate treatment side effects. As severity of side effects increased, patients were less likely to feel that treatment was worthwhile but a proportion were still willing to accept these for a relatively short increase in the time drugs controlled the cancer.

Side effects of treatment and quality of life among patients with schizophrenia

2011 ◽  
Vol 26 (S2) ◽  
pp. 1450-1450
Author(s):  
J. Ben Thabet ◽  
I. Feki ◽  
R. Sallemi ◽  
J. Masmoudi ◽  
L. Zouari ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Negative Symptoms ◽  
Rating Scale ◽  
Treatment Compliance ◽  
University Hospital ◽  
Average Score ◽  
Treatment Side Effects ◽  
Impaired Quality

The aim of our study was to assess the treatment side effects and their implications on quality of life in a population of schizophrenic patients.We included 50 patients with schizophrenia treated at Hthe psychiatry department of the university hospital in Sfax (Tunisia). We used the PANSS, the UKU side effect rating scale and the SF-36 to assess, respectively, the severity of disease, the treatment side effects and the quality of life. The statistical analysis was carried out by software SPSS.The assessment of quality of life revealed a global average score of 59.11 and an alteration in 54% of patients. Impaired quality of life was significantly correlated with irregular follow-up (p = 0.02), bad treatment compliance (p = 0.016) and polytherapy (p = 0.024). The presence of side effects which affect either moderately or severely daily activity was significantly correlated with impaired quality of life (p = 0.007). The presence of side effects was correlated in a significant way with altered quality of life (p = 0,007).Our study showed a relatively high frequency of side effects of treatment in patients with schizophrenia. They were correlated with impaired quality of life. They are also factors of bad compliance. Reduction and prevention of side effects requires the use of atypical antipsychotics which are better tolerated and more active on negative symptoms. However, they pose the problem of high costs. But it must be noted here that the overall cost of disease is higher with conventional antipsychotics than with atypical ones.

Sign in / Sign up

Export Citation Format

Share Document